Compare FICO & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FICO | RVPH |
|---|---|---|
| Founded | 1956 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2B | 71.0M |
| IPO Year | 1987 | N/A |
| Metric | FICO | RVPH |
|---|---|---|
| Price | $1,736.71 | $0.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $1,999.83 | $3.33 |
| AVG Volume (30 Days) | 181.6K | ★ 7.9M |
| Earning Date | 02-03-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.78 | N/A |
| EPS | ★ 26.54 | N/A |
| Revenue | ★ $1,990,869,000.00 | N/A |
| Revenue This Year | $24.77 | N/A |
| Revenue Next Year | $17.55 | N/A |
| P/E Ratio | $65.22 | ★ N/A |
| Revenue Growth | ★ 15.91 | N/A |
| 52 Week Low | $1,300.00 | $0.25 |
| 52 Week High | $2,217.60 | $2.17 |
| Indicator | FICO | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.99 | 26.65 |
| Support Level | $1,726.39 | $0.48 |
| Resistance Level | $1,767.90 | $0.63 |
| Average True Range (ATR) | 47.54 | 0.07 |
| MACD | -11.39 | -0.04 |
| Stochastic Oscillator | 18.19 | 6.44 |
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.